Natural Product (NP) Details
General Information of the NP (ID: NP0050) | |||||
---|---|---|---|---|---|
Name |
Phenethyl isothiocyanate
|
||||
Synonyms |
2-Phenylethyl isothiocyanate; Phenethyl isothiocyanate; 2257-09-2; Phenylethyl isothiocyanate; (2-Isothiocyanatoethyl)benzene; Phenethyl mustard oil; Benzene, (2-isothiocyanatoethyl)-; Phenylaethylsenfoel; 2-isothiocyanatoethylbenzene; PEITC; Phenylethyl mustard oil; PHENETHYLISOTHIOCYANATE; phenethyl-isothiocyanate; 2-phenethyl isothiocyanate; 2-phenylethylisothiocyanate; ISOTHIOCYANIC ACID, PHENETHYL ESTER; beta-Phenethyl isothiocyanate; MFCD00004821; beta-Phenylethyl isothiocyanate; CHEBI:351346; NSC 87868; UNII-6U7TFK75KV; 6U7TFK75KV; CHEMBL151649; .beta.-Phenethyl isothiocyanate; 1-Isothiocyanato-2-phenylethane; .beta.-Phenylethyl isothiocyanate; 1-(2-isothiocyanatoethyl)benzene; (2-Isothiocyanato-ethyl)-benzene; Isothiocyanic Acid 2-Phenylethyl Ester; 2-phenylethanisothiocyanate; Phenylaethylsenfoel [German]; 1-ISOTHIOCYANATO-2-PHENYLETHANE (1,1,2,2-D4); CCRIS 3146; EINECS 218-855-5; BRN 2084162; ACMC-1CLKQ; DSSTox_CID_1120; WLN: SCN2R; beta-phenethylisothiocyanate; ss-Phenethyl isothiocyanate; Epitope ID:138724; b-phenylethyl isothiocyanate; DSSTox_RID_75951; DSSTox_GSID_21120; 2-phenyl ethyl isothiocyanate; SCHEMBL156960; Phenethyl isothiocyanate, 99%; DTXSID5021120; IZJDOKYDEWTZSO-UHFFFAOYSA-; (2-Isothiocyanatoethyl)benzene #; 2-Phenylethyl isothiocyanate, FG; HMS1783C17; HMS3870G13; NSC87868; ZINC2022074; Tox21_200100; (2-Isothiocyanatoethyl)benzene, 9CI; ANW-13714; BBL009999; BDBM50240850; NSC-87868; SBB002732; STK397325; AKOS000119469; DB12695; JC-5411; MCULE-7681211375; NE22461; Isothiocyanic acid beta-phenylethyl ester; NCGC00248526-01; NCGC00257654-01; AC-12769; AS-17373; BP-12941; NCI60_041942; U800; CAS-2257-09-2; DB-045947; Isothiocyanic acid .beta.-phenylethyl ester; FT-0604634; P0986; Phenethyl isothiocyanate, analytical standard; ST50330661; 4-12-00-02476 (Beilstein Handbook Reference); A816267; J-802164; Q7181339; W-107466; BRD-K56700933-001-02-1; F0001-0795
Click to Show/Hide
|
||||
Species Origin | Nasturtium officinale ... | Click to Show/Hide | |||
Nasturtium officinale | |||||
Disease | Prostate cancer [ICD-11: 2C82] | Phase 2 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C9H9NS
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC=C(C=C1)CCN=C=S
|
||||
InChI |
1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2
|
||||
InChIKey |
IZJDOKYDEWTZSO-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 2257-09-2
|
||||
ChEBI ID | |||||
Herb ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Dibenzoylmethane | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
VCaP | CVCL_2235 | Prostate carcinoma | Homo sapiens | |||
In-vivo Model | For a xenograft model, 2 * 106 VCaP cells per 0.1 ml suspended in a mixture of Matrigel and RPMI 1640 medium (1 : 1) were injected subcutaneously into the back of the mice. | |||||
Experimental
Result(s) |
Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgenindependent growth of prostate cancer cells. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Up-regulation | ROS generation | ||||
In-vitro Model | Meso4 | CVCL_H678 | Pleural epithelioid mesothelioma | Homo sapiens | ||
Meso11 | CVCL_H670 | Pleural epithelioid mesothelioma | Homo sapiens | |||
Meso13 | CVCL_H672 | Pleural epithelioid mesothelioma | Homo sapiens | |||
Meso34 | CVCL_H675 | Pleural epithelioid mesothelioma | Homo sapiens | |||
Meso47 | CVCL_H680 | Pleural epithelioid mesothelioma | Homo sapiens | |||
Meso56 | CVCL_H681 | Pleural epithelioid mesothelioma | Homo sapiens | |||
Meso96 | CVCL_H683 | Pleural epithelioid mesothelioma | Homo sapiens | |||
Meso76 cells established from pleural fluids of patients | Malignant Pleural Mesothelioma | Homo sapiens | ||||
Meso152 cells established from pleural fluids of patients | Malignant pleural mesothelioma | Homo sapiens | ||||
Experimental
Result(s) |
The combination of cisplatin with the natural compound PEITC induces a strong MPM cell death, while remaining safe for PMC, with limited emergence of cell resistance compared to drugs used alone. |